GlassScriptPhysician profile
Mark Alan Wood
NPI 1356312110
$3,261.97
in general payments reported to CMS, 2019-2025
35 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $466 · 2021: $452 · 2022: $220 · 2023: $376 · 2024: $230 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.04 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $345.92 | 2019-2025 | |
| Amarin Pharma, INC. | $274.32 | 2019-2021 | |
| Abbvie INC. | $249.41 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $237.58 | 2019 | |
| Lilly USA, LLC | $188.65 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $173.30 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $161.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.06 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $155.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $146.74 | 2019-2021 | |
| Astellas Pharma US INC | $138.56 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.31 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $67.94 | 2019-2024 | Otezla, Repatha |
| Ultragenyx Pharmaceutical INC. | $58.09 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $42.60 | 2019 | |
| Xeris Pharmaceuticals, INC. | $41.26 | 2023-2025 | Gvoke Hypopen |
| Eisai INC. | $32.70 | 2020-2021 | |
| Glaxosmithkline, LLC. | $31.52 | 2019-2023 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $25.30 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $24.63 | 2021 | |
| Merck Sharp & Dohme LLC | $24.41 | 2019 | |
| Cipher Pharmaceuticals US LLC | $18.51 | 2025 | Natroba, Spinosad |
| Shield Therapeutics INC | $18.18 | 2023 | Accrufer |
| Acadia Pharmaceuticals INC | $18.11 | 2023 | Nuplazid |
| Phathom Pharmaceuticals, INC. | $18.00 | 2025 | Voquezna |
| Neurocrine Biosciences, INC. | $17.41 | 2023 | Ingrezza |
| Lundbeck LLC | $16.59 | 2024 | Rexulti |
| Medtronic, INC. | $16.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.05 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.80 | 2021 | |
| Dexcom, INC. | $13.58 | 2021 | |
| Esperion Therapeutics, INC. | $13.09 | 2020 | |
| Allergan, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.